Molecule intelOpportunity: StrongEssential

Dacarbazine

11 brands · 9 companies · product forms

ATC: L01AX04

Opportunity snapshot

Launch attractiveness
50
Market saturation
23
Price room
100
Regulatory risk
0
11
brands
9
companies
Rs 993.92
median price
12
price points
16.86x
price spread
100
confidence %

Who competes here

Top companies by brand count — fragmented market (no dominant player) · leader share 18%

Price room

Across observed sources and strengths
CheapestRs 475
MedianRs 993.92
Most expensiveRs 8,009.96
Spread16.86×
Sources: DRAP-official, DVAGO, Servaid

max/min price ratio 16.86x across 12 trusted points (Rs 475.0-8009.96). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Brands & products on the market

Sample of 6 live products for Dacarbazine — each links to its own medicine page.

Why this score

Launch attractiveness

40% supply-gap(25) + 25% price-variation(100) + 20% low-competition(77) + 15% supply-disruption(0), damped by confidence(100). Higher = more attractive, less crowded opportunity.

Market saturation

9 canonical companies and 11 brands compete (saturation pegged at 30 companies / 150 brands).

Price room

max/min price ratio 16.86x across 12 trusted points (Rs 475.0-8009.96). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Regulatory risk

No DRAP alerts on this molecule's brands.

Confidence

Full coverage.

Packaged brief for this strong opportunity?

Molecule page + company profiles + price-room analysis are the pilot package for pharma teams.

See packaged reports All 3868 molecules

Molecule intelligence as of 2026-07-30. Brand/company counts from DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.